Jin-shui Huan-xian granule

PreclinicalSmall molecule

HHenan University of Traditional Chinese Medicine

Jin-shui Huan-xian granule is one of 46 small molecule programs targeting Treatment. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TreatmentUnknown status

Pulmonary FunctionNot yet recruiting

TreatmentPreclinical

Unknown status

Pulmonary FunctionPreclinical

Not yet recruiting

Competition

Competitive Landscape

350 competitors in Treatment

#DrugCompanyPhaseTrials

Biltricide

Bayer

Preclinical

4 2

Dexilant

Takeda

Preclinical

2 3

Alfenta

Jazz Pharmaceuticals

Preclinical

1 4

Niclocide

Bayer

Preclinical

1 5

Minipress

Pfizer

Preclinical

1 6

Hivid

CConrado Roberto Hoffmann Filho

Preclinical

6 7

Clomid

Ferring

Preclinical

1 8

Aurlumyn

BBTG International Inc.

Preclinical

1 9

Lotemax

PPharmos

Preclinical

1 10

Norpramin

VValidus Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

N/ANot yet recruiting

Pulmonary Function

NCT06914713

Clinical

Trials by Indication[1]

Pulmonary Function1 trial

Jin-shui Huan-xian Formula for Retarding the Decline of Pulmonary Function in IPF

Not yet recruiting·HHenan University of Traditional Chinese Medicine·N/A·NCT06914713·384 enrolled

Treatment1 trial

Jin-shui Huan-xian Granule in the Treatment of IPF

Unknown status·HHenan University of Traditional Chinese Medicine·N/A·NCT04187690·312 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Jin-shui Huan-xian granule. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Jin-shui Huan-xian granule compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Jin-shui Huan-xian granule. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Henan University of Traditional Chinese Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: HHenan University of Traditional Chinese Medicine

Jin-shui Huan-xian granule

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Pulmonary Function1 trial

Treatment1 trial

References

Drug Info

Quick Facts

Related News